World Mosquito Program Noumea - Human Sample Component

The dengue, Zika and chikungunya arboviruses represent potentially severe infections to which the New Caledonian population is exposed. In the absence of specific treatment or vaccine, vector control remains the method of choice to limit their spread. However, the traditional methods of prevention and vector control measure today face their limits: mosquito resistance to insecticides, difficulty of access and destruction of breeding areas... The World Mosquito Program Noumea project is based on the artificial colonization of the mosquito vector Aedes aegypti by the endosymbiotic bacteria Wolbachia, which reduces its ability to transmit arboviruses. The breeding of mosquitoes carrying the bacterium Wolbachia in the laboratories of the Institut Pasteur of New Caledonia requires the use of human blood samples for mosquito gorging.

The objective of the research is to generate, maintain and amplify Aedes aegypti Caledonian lineages carrying the Wolbachia bacteria for the planned insect release program in Noumea.

Study Overview

• Status: Recruiting
• Conditions: Arbovirus Infections
• Intervention / Treatment: Other: Blood donations of hemochromatosis or polycythemia patients; Other: Blood donations of healthy donors

Detailed Description

The dengue, Zika and chikungunya arboviruses represent potentially severe infections to which the New Caledonian population is exposed. In the absence of specific treatment or vaccine, disease vector control remains the method of choice to limit their spread. However, the traditional methods of prevention and disease vector control must today face their limits: mosquito resistance to insecticides, difficulty of access and destruction of breeding areas... The World Mosquito Program Noumea project is based on the artificial colonization of the mosquito vector Aedes aegypti by the endosymbiotic bacterium Wolbachia, which reduces its ability to transmit arboviruses. The breeding of mosquitoes carrying the bacterium Wolbachia in the laboratories of the Institut Pasteur of New Caledonia requires the use of human blood samples for mosquito gorging.

The objective of the research is to generate, maintain and amplify Aedes aegypti Caledonian lineages carrying the bacterium Wolbachia for the planned insect release program in Noumea.

The establishment of Wolbachia in Aedes aegypti populations in Noumea should lead to the reduction of active transmission of dengue, Zika and chikungunya in the municipality.

• Study Type: Observational
• Enrollment (Anticipated): 500

Contacts and Locations

• Study Contact: Name: Vincent Richard; Phone Number: +687 27.26.66; Email: vrichard@pasteur.nc
• Study Contact Backup: Name: Nicolas Pocquet; Phone Number: +687 27.26.66; Email: npocquet@pasteur.nc

Study Locations

• France
  • Nouvelle-Calédonie
    • Nouméa, Nouvelle-Calédonie, France, 98 849
      • Recruiting
      • Centre Hospitalier de Nouvelle-Calédonie
      • Contact: Frédéric Touzain, MD; Phone Number: +687209800; Email: frederic.touzain@cht.nc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications, and healthy donors.

Description

Inclusion Criteria:

• All adult hemochromatosis or polycythemia patients or healthy donors have given their written consent to participate in the study and for the collection of a blood sample.

Exclusion Criteria:

• Participation refusal
• Minor person
• Positive result by Reverse transcription polymerase chain reaction RT-PCR for arboviruses
• Invalid qualification of the blood donation

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Hemochromatosis or polycythemia patients; Blood samples from hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications. Blood bag (volume of blood: from 450 to 500 mL).	Other: Blood donations of hemochromatosis or polycythemia patients; Blood samples are from blood donations of hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.
Healthy donors; Blood samples from healthy donors. Blood bag (volume of blood: from 450 to 500 mL).	Other: Blood donations of healthy donors; Blood samples are from blood donations of healthy donors.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Generation of Aedes aegypti Caledonian lineages carrying the Wolbachia bacteria	Generation of Aedes aegypti Caledonian lineages carrying the Wolbachia bacteria for the planned insect release program in Noumea by measuring the Aedes aegypti female gorging rate	36 months
Maintenance and amplification of Aedes aegypti Caledonian lineages carrying the Wolbachia bacteria	Maintenance and amplification of Aedes aegypti Caledonian lineages carrying the Wolbachia bacteria for the planned insect release program in Noumea by measuring the number of eggs per Aedes Aegypti female gorged	36 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Vector competence assessment of the different Aedes aegypti Caledonian lineages	Assessment of the vector competence for the dengue, Zika and chikungunya viruses of the different Aedes aegypti Caledonian lineages with or without Wolbachia bacteria carriage by measuring the transmissibility reduction of Aedes aegypti carrying Wolbachia for arboviruses	36 months

Collaborators and Investigators

• Sponsor: Institut Pasteur
• Collaborators: Institut Pasteur of New Caledonia
• Investigators: Principal Investigator: Frédéric Touzain, Hospital Center of New Caledonia; Principal Investigator: Myrielle Dupont-Rouzeyrol, Institut Pasteur of New Caledonia

Study record dates

Study Major Dates

• Study Start (Actual): June 25, 2018
• Primary Completion (Anticipated): June 1, 2023
• Study Completion (Anticipated): June 1, 2023

Study Registration Dates

• First Submitted: May 28, 2018
• First Submitted That Met QC Criteria: June 8, 2018
• First Posted (Actual): June 11, 2018

Study Record Updates

• Last Update Posted (Actual): February 15, 2022
• Last Update Submitted That Met QC Criteria: February 14, 2022
• Last Verified: February 1, 2022

More Information

Terms related to this study

• Keywords: Arbovirus
• Additional Relevant MeSH Terms: Virus Diseases; Infections; Vector Borne Diseases; Arbovirus Infections
• Other Study ID Numbers: 2017-036

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No